All In Biotech

Drug Trial Radar · NCT00412958

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

A Multicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial

Last checked: Nov 20, 2026Latest source record: Dec 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Dec 2006

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
ThromboGenicsIndustry
Sponsor type
Industry
First posted
Dec 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.

Conditions

  • Vitrectomy

Interventions

  • Ocriplasmin 25µgDrug

    Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.

  • Ocriplasmin 75µgDrug

    Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.

  • Ocriplasmin 125µgDrug

    Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.

  • PlaceboDrug

    Intravitreal injection of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients Achieving Total Posterior Vitreous Detachment (PVD) Without Creation of an Anatomical DefectTime frame: Day 7

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Retina Centers, P.C.

    Tucson, Arizona

  • VMR Institute

    Huntington Beach, California

  • Jules Stein Eye Institute/UCLA

    Los Angeles, California

  • Retinal Consultants of San Diego

    Poway, California

  • Retinal Consultants Medical Group

    Sacramento, California

  • National Ophtlamic Research Institute

    Fort Meyers, Florida

  • Center for Retina and Macular Disease

    Winter Haven, Florida

  • Rush University Med. Ctr

    Chicago, Illinois

  • Mailing add: New England Eye Center - Tufts

    Boston, Massachusetts

  • Associated Retinal Consultants, P.C.

    Royal Oak, Michigan

  • Vitroretinal Surgery, PA

    Minneapolis, Minnesota

  • Retina Vitreous Centre, PA

    New Brunswick, New Jersey

  • Columbia University - Harkness Eye Institute

    New York, New York

  • Retina Vitreous Surgeons of Central NY

    New York, New York

  • Duke Eye Center

    Durham, North Carolina

  • Retina Association of Cleveland

    Lakewood, Ohio

  • Allegheny Ophthalmic & Orbital Associates, P.C.

    Pittsburgh, Pennsylvania

  • Vanderbilt Eye Institute

    Nashville, Tennessee

  • Vitreoretinal Consultants

    Houston, Texas

  • Valley Retina Institute, P.A.

    McAllen, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.